Mackenzie Financial’s Agios Pharmaceuticals AGIO Stock Holding History

Mackenzie Financial’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.47M	Buy	+44,087	New	+$1.54M	﹤0.01%	1122

Other funds holding AGIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Mackenzie Financial's AGIO Position: Q3 2026 in Review

Mackenzie Financial opened a new position in Agios Pharmaceuticals (AGIO) in Q3 2026: 44,087 shares worth $1.47M. The stake represents ﹤0.01% of the portfolio and ranks #1122 among its holdings.

51 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

Mackenzie Financial held 44,087 shares of Agios Pharmaceuticals worth $1.47M as of Q3 2026.
Agios Pharmaceuticals was a new Mackenzie Financial position in Q3 2026.
Agios Pharmaceuticals made up ﹤0.01% of Mackenzie Financial's portfolio in Q3 2026, its #1122 holding.
51 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.